Gland Pharma receives USFDA’s tentative approval for Latanoprostene Bunod Ophthalmic Solution
The product is bioequivalent and therapeutically equivalent to the reference listed drug
The product is bioequivalent and therapeutically equivalent to the reference listed drug
The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India
The inspections concluded with no Form 483 observations or significant critical findings
Ephedrine Sulfate injection USP, 50 mg/mL is indicated for the treatment of clinically important hypotension
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
Doxorubicin Hydrochloride Liposome Injection (RLD Doxil) had estimated annual sales of USD 42 million in the U.S. (IQVIA MAT May 2024)
The inspection closed with five observations which were more of procedural changes with none of these related to data integrity
The company will address these observations within the stipulated timeline
Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension
Subscribe To Our Newsletter & Stay Updated